Expression Of PHGDH And MTHFD2 In Endometrial Carcinoma And Evaluation Of Its Clinical Application Value

Background:As one of the three major malignant tumors of the female reproductive tract,endometrial cancer is a group of epithelial malignant tumors that occur in the endometrium,which Is the sixth most common malignant disease in the world.Currently,study found that the incidence of endometrial cancer is increasing year by year,and the patient group of endometrial cancer also promotes younger staff.These remind us to pay more attention to the study of endometrial cancer.At present,the mechanism of occurrence and development of endometrial cancer is still unclear.We hope to find out the ways to diagnose and treat endometrial cancer by studying the way of endometrial cancer.Glycerol-3-phosphate dehydrogenase(PHGDH)is an important catalytic enzyme in the synthesis of L-serine.The methylenetetrahydrofolate dehydrogenase 2(MTHFD2)gene encodes a mitochondrial bifunctional protein which is a key enzyme in the mitochondrial pathway of folate metabolism.These two proteins are expressed at high levels in many malignant cells,which is different in normal endometrial tissues.We found that these two proteins are involved in folate metabolism,that is currently recognized as a pathway of the proliferation of malignant cell.We hypothesize that PHGDH and MTHFD2 can be the new research direction for the diagnosis and treatment of endometrial cancer.Is there a certain application value in clinical practice?Objective:The expression of PHGDH and MTHFD2 in different types of endometrial tissues was detected to understand the relationship between the expression of these two proteins in endometrial cancer tissues and different clinicopathological features.To analyze the possible role of PHGDH and MTHFD2 in the development and progression of endometrial cancer.To evaluate the possible clinical significance of PHGDH and MTHFD2 in the diagnosis and treatment of endometrial cancer.Method:A total of 63 specimens of endometrial cancer were collected.55 cases of endometrial hyperplasia and 20 cases of normal endometrial tissue were randomly selected.The wax blocks of the corresponding regional tissues were taken for experiment.The expression of PHGDH and MTHFD2 in different endometrial tissues was detected by immunohistochemistry.Result:1?The strongly expression rate of PHGDH and MTHFD2 in normal endometrial tissue,endometrial hyperplasia tissue and endometrial carcinoma tissues increased gradually(P<0.05).2?The expression of PHGDH in endometrial carcinoma was associated with surgical pathological stage,vascular thrombosis and lymphatic metastasis(P<0.0125),which was not related to age,differentiation and depth of invasion(P>0.0125).3?The expression of MTHFD2 in endometrial carcinoma was associated with surgical pathological stage(P<0.0125),and was not associated with age,degree of differentiation,depth of invasion,presence or absence of vascular tumor thrombus and lymphatic metastasis(P>0.0125).4.In the process of transformation into endometrial cancer tissues,PHGDH was positively correlated with MTHFD2 expression(P=0.000,r=0.652).Conclusion:1.The protein expression of PHGDH and MTHFD2 increased gradually from normal endometrium,proliferative endometrium to endometrial cancer,suggesting that these two enzymes may be involved in the development of endometrial cancer.At the same time,the different expressions of PHGDH and MTHFD2 in endometrial cancer under different clinicopathological features make these two proteins may help the early diagnosis of endometrial cancer,assisting the assessment of preoperative surgical staging,treatment effect and the selection of clinical treatment modalities.2.The specificity and sensitivity of PHGDH in endometrial cancer is higher than that of MTHFD2.The joint detection of two proteins can not increase their diagnostic value.3.In the process of transformation into endometrial cancer tissue,PHGDH and MTHFD2 expression showed a strong positive correlation,suggesting that these two proteins may become a breakthrough in endometrial cancer targeted therapy.